Takeda to cut 2,800 jobs
pharmafile | January 19, 2012 | News story | Business Services, Research and Development, Sales and Marketing | Nycomed, Takeda, job cuts
Takeda has announced plans to significantly reduce its global headcount over the next four years following its merger with Nycomed.
The consolidation plans will account for 2,100 job losses in Europe and 700 in the US, amounting to around 10% of its workforce.
Takeda’s plans which will come to fruition by the end of fiscal 2015 hope to streamline its operations across the board, following September’s €9.6 billion acquisition.
Takeda’s President and chief executive Yasuchika Hasegawa, said: “While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.”
The company said it will achieve cost synergies of approximately 200 billion yen as it reduces its R&D and commercial functions. The cost to implement the changes is set at 70 billion yen.
“The combination of Takeda and Nycomed brought together Takeda’s strong presence in the Japanese and US markets, with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,” Hasegawa added.
Takeda’s ‘2011-2013 Mid-Range Plan’ states it still intends to invest strongly in R&D and will focus on core therapeutic areas.
Between them the companies’ therapy areas include metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Brett Wells
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
